PuSH - Publikationsserver des Helmholtz Zentrums München

178 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
Li, L.S.* et al.: Type II JAK2 inhibitor NVP-CHZ868 is active in vivo against JAK2-dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs). Blood 124 (2014)
Stemberger, C.* et al.: Lowest numbers of primary CD8+ T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood 124, 628-637 (2014)
Tassara, M.* et al.: Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood 123, 4027-4036 (2014)
von der Heide, E.K.* et al.: Molecular alterations in bone marrow mesenchymal stroma cells of AML patients. Blood 124 (2014)
Vosberg, S. et al.: Copy Number Alteration (CNA) analysis in targeted sequencing data from Acute Myeloid Leukemia (AML) patients with chromosome 9q deletion. Blood 124 (2014)
Krappmann, D.: Shaping oncogenic NF-κB activity in the nucleus. Blood 122, 2146-2147 (2013)
Neumann, M.* et al.: Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 121, 4749-4752 (2013)
Opatz, S.* et al.: Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia. Blood 122, 1761-1769 (2013)
Alves, C.C. et al.: Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. Blood 119, 4224-4227 (2012)
Greif, P.A. et al.: GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood 120, 395-403 (2012)
Huang, J.* et al.: Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood 120, 4873-4881 (2012)
Metzeler, K.H.* et al.: High expression of Lymphoid Enhancer-binding Factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood 120, 2118-2126 (2012)
Schlitzer, A.* et al.: Tissue-specific differentiation of a circulating CCR9- pDC-like common dendritic cell precursor. Blood 119, 6063-6071 (2012)
Schneider, F.* et al.: The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. Blood 119, 4383-4386 (2012)
Spranger, S. et al.: TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. Blood 119, 3440-3449 (2012)
Thomas, M.F.* et al.: Eri1 regulates microRNA homeostasis and mouse lymphocyte development and anti-viral function. Blood 120, 130-142 (2012)
de Andrés-Aguayo, L.* et al.: Musashi 2 is a regulator of the HSC compartment identified by a retroviral insertion screen and knockout mice. Blood 118, 554-564 (2011)
Ehrhardt, H. et al.: Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule. Blood 118, 6123-6131 (2011)
Hammerschmidt, W.: What keeps the power on in lymphomas? (Comment on Vereide and Sudgen, page 1977) Blood 117, 1777-1778 (2011)
Hampel, F. et al.: CD19-independent instruction of murine marginal zone B-cell development by constitutive Notch2 signaling. Blood 118, 6321-6331 (2011)